Key Players
Competitive Landscape
The exosome development and manufacturing market brings together integrated CDMOs, cell-platform providers, analytical technology suppliers and therapeutic developers. Competition depends on source-cell control, scalable purification and the ability to transfer exosome processes into regulated manufacturing environments.
Investment has moved toward manufacturing scale-up, regional production partnerships and engineered exosome therapeutics since 2025. Lonza expanded its exosome manufacturing activities through an agreement with RION Therapeutics in September 2025 to support large-scale production of exosome-based therapeutics. Evox Therapeutics partnered with Rett Syndrome Research Trust in February 2026 to evaluate ExoEdit for gene-editing delivery. RoosterBio entered a strategic technology and supply partnership with Made Scientific in May 2026 to connect standardized MSC and extracellular-vesicle inputs with commercial GMP production. Buyers still evaluate capacity and yield, but sponsors increasingly compare suppliers on process transfer, release methods and manufacturing consistency.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| RION Therapeutics engaged Lonza to scale manufacturing of exosome-based therapeutics, September 2025 | Clinical programs require larger batches under GMP conditions | Sponsors increasingly outsource scale-up and technology transfer | Process development, GMP manufacturing and commercial production services |
| Evox Therapeutics partnered with Rett Syndrome Research Trust to evaluate ExoEdit delivery, February 2026 | Developers seek targeted delivery systems for genetic disorders | Engineered exosome platforms move toward gene-editing applications | Rare-disease therapeutics and precision delivery programs |
| Made Scientific and RoosterBio formed a strategic technology and supply partnership, May 2026 | Sponsors need standardized manufacturing inputs | Integrated manufacturing platforms reduce transfer risk | Clinical supply and commercial-scale extracellular-vesicle production |
FUJIFILM Biotechnologies, Sartorius, Thermo Fisher Scientific, Aegle Therapeutics and Creative Biolabs compete through manufacturing support, analytical technologies and exosome platform development. No major dated developments were identified for these companies during the review period.
Source: Future Market Insights analysis based on company announcements and public disclosures, 2025-2026.
Lonza and FUJIFILM Biotechnologies provide integrated development and GMP manufacturing capabilities. RoosterBio supports standardized cell and media platforms, while Sartorius and Thermo Fisher Scientific support purification and analytical workflows. Evox Therapeutics and Aegle Therapeutics focus on therapeutic applications of exosome technologies.
Who leads the exosome development and manufacturing market?
Lonza is among the leading manufacturing providers due to its process-development, technology-transfer and GMP production capabilities. FUJIFILM Biotechnologies also maintains a strong position through established biologics and advanced therapy manufacturing infrastructure.
Which suppliers provide GMP manufacturing and process-transfer capabilities?
Lonza, FUJIFILM Biotechnologies and Thermo Fisher Scientific provide manufacturing support for regulated development programs. Their activities include process development, analytical support, technology transfer and GMP production.
Which companies focus on therapeutic exosome platforms?
Evox Therapeutics and Aegle Therapeutics focus on therapeutic applications of exosome technologies. Evox develops engineered exosome delivery approaches, while Aegle advances extracellular-vesicle therapies for regenerative and inflammatory indications.
Which suppliers support production and analytical workflows?
RoosterBio, Sartorius and Creative Biolabs support upstream processing, purification, characterization and scale-up activities. Their products and services help sponsors improve batch consistency and analytical control during development.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Lonza Group AG | Global CDMO | Process development, technology transfer and GMP manufacturing for exosome therapeutics |
| FUJIFILM Biotechnologies | Global CDMO | Development and manufacturing services for advanced biologics and cell-based therapies |
| RoosterBio, Inc. | Cell-platform provider | MSC-based cells, media systems and exosome manufacturing support |
| Sartorius AG | Global bioprocess supplier | Purification, filtration, analytics and upstream processing technologies |
| Thermo Fisher Scientific Inc. | Global services provider | GMP manufacturing, analytical testing and advanced therapy support |
| Evox Therapeutics Ltd. | Therapeutic developer | Engineered exosome delivery technologies and ExoEdit platform |
| Aegle Therapeutics Corp. | Therapeutic developer | Extracellular-vesicle therapeutics for regenerative medicine applications |
| Creative Biolabs | Research and service provider | Exosome isolation, characterization and custom development services |
Research Methodology
The companies mapped here illustrate the market structure rather than an exhaustive ranking. Inclusion requires current, verifiable evidence that a company provides exosome manufacturing, process development, analytical support, therapeutic development or related extracellular-vesicle technologies. Evidence comes from company announcements, regulatory publications, product literature and public filings. Capabilities are attributed to the stated company or platform and are not generalized across unrelated business activities. Market-share assessments remain proprietary FMI estimates for the 2026-2036 forecast period.
